Table 1.
Demographic and baseline clinical characteristics in CTEPH patients with and without adverse clinical outcomes.
| Variable |
Study cohort
( N = 151) |
Adverse clinical events | P -value | |
|---|---|---|---|---|
|
Event free
( n = 79) |
With event
( n = 72) |
|||
| Age (y) | 50.9 ± 14.1 | 51.6 ± 13.9 | 50.2 ± 14.3 | 0.550 |
| Male, n (%) | 43 (28.5) | 21 (26.5) | 22 (30.5) | 0.589 |
| Body surface area (m2) | 1.7 ± 0.2 | 1.7 ± 0.2 | 1.7 ± 0.2 | 0.905 |
| WHO functional class | 0.003 | |||
| I | 6 (4.0) | 6 (7.6) | 0 (0) | |
| II | 68 (45.0) | 46 (58.2) | 22 (30.6) | |
| III | 60 (39.7) | 27 (34.2) | 33 (45.8) | |
| IV | 17 (11.3) | 0 (0) | 17 (23.6) | |
| Disease duration (mo) | 21.8 (2–168) | 11.5 (2–34) | 33.0 (3–168) | <0.0001 |
| 6-min walk distance (m) | 372 (98–630) | 412 (196–630) | 328 (190–410) | <0.0001 |
| NT-proBNP (pg/ml) | 941.54 ± 1075.7 | 646.9 ± 1039.3 | 1971.1 ± 1755.6 | <0.0001 |
| Basic hemodynamics data | ||||
| RA pressure (mm Hg) | 5.9 ± 4.6 | 4.6 ± 3.6 | 7.4 ± 5.3 | <0.0001 |
| Mean PA pressure (mm Hg) | 47.4 ± 12.5 | 44.2 ± 12.3 | 51.0 ± 11.7 | 0.001 |
| Cardiac index (L/min per m2) | 2.5 ± 0.8 | 2.8 ± 0.9 | 2.2 ± 0.6 | <0.0001 |
| Pulmonary vascular resistance (wood units) | 10.3 ± 5.2 | 8.1 ± 12.9 | 24.6 ± 21.9 | 0.278 |
| PH medical treatment | 0.203 | |||
| Rivaroxaban/Warfarin | 151 (100) | 79 (100) | 72 (100) | |
| Riociguat | 97 (64.2) | 51 (64.6) | 46 (63.9) | |
| PDE-5 inhibitors | 38 (25.2) | 18 (22.8) | 20 (27.8) | |
| Endothelin-1 inhibitors | 31 (20.5) | 14 (17.7) | 17 (23.6) | |
| Combined therapy | 19 (12.6) | 6 (7.6) | 13 (18.1) | |
| Follow-up (mo) | 19.7 (0.5–54) | 27.9 (1–54) | 10.7 (0.5–25) | <0.0001 |
CTEPH, chronic thromboembolic pulmonary hypertension; NT-proBNP, N-terminal pro–B-natriuretic peptide; RA, right atrium; PA, pulmonary artery; PAH, pulmonary arterial hypertension; PDE-5, phosphodiesterase-5. Data are expressed as mean ± SD, number (percentage), or median (interquartile range). P-values indicate significance between patients with and those without adverse clinical outcomes. Bold values indicate statistical significance of the tested parameters.